Monday 16 November 2026
Export KYNB’s income statement to Excel — free account
Kyntra Bio Inc
KYNBKyntra Bio Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, down 78.3% from fiscal 2024.
- Revenue
- n/m
- EPS
- n/m
- Free cash flow
- n/m
Quarter to June 2026, against a year earlier
3.44
0.15
−4.18%
Follow KYNB
Alert me
Revenue to profit Twelve months to 30 June 2026
Of every $100 of revenue, $3967.77 was left as profit. Gross margin has fallen three quarters running, from 167.1% to 6.3%. What is an income statement?
| Revenue | 0.0 | 100.0% |
|---|---|---|
| Cost of revenue | 0.0 | −93.7% |
| Gross profit | 0.0 | 6.3% |
| Research & development | 0.0 | −495.2% |
| Selling, general & admin | 0.0 | −599.4% |
| Other operating costs | 0.0 | −1.5% |
| Operating income | −0.1 | −1089.8% |
| Other income, net | 0.0 | 420.2% |
| Income tax | 0.0 | 2.0% |
| Other items | +0.2 | 4635.4% |
| Net income | 0.2 | 3967.8% |
| Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.0B | $0.0B |
| Operating income | $0.0B | $0.0B | $0.0B | −$0.1B |
| Net income | $0.2B | $0.2B | $0.2B | $0.2B |
| Net margin (right axis) | 2598.6% | 2848.6% | 2199.4% | 3967.8% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Revenue |
4.62 | 7.44 | 6.44 | 8.30 |
+8 more TTM periods Free account |
Cost of Revenue |
4.33 | 4.41 | 0.56 | (5.57) | |
Gross Profit |
0.29 | 3.03 | 5.88 | 13.87 | |
R&D Expenses |
22.86 | 21.91 | 23.52 | 23.12 | |
SG&A Expenses |
27.67 | 25.47 | 27.71 | 28.81 | |
Operating Income |
(50.31) | (44.79) | (45.89) | (39.52) | |
Non-operating Income/Expense |
19.40 | (11.87) | (12.40) | (12.83) | |
Non-operating Interest Expenses |
9.29 | 8.93 | 8.76 | 8.57 | |
| (30.91) | (56.66) | (58.29) | (52.35) | ||
Income Tax Provision |
(0.09) | — | (0.09) | — | |
Income after Tax |
(30.91) | (56.57) | (58.20) | (52.26) | |
Net Income Common |
183.19 | 163.62 | 183.45 | 215.65 | |
EPS (Basic) |
45.30 | 40.46 | 45.47 | 53.48 | |
EPS (Diluted) |
45.30 | 40.46 | 45.37 | 53.38 | |
Shares (Basic, Weighted) |
4.05 | 4.04 | 4.04 | 4.03 | |
Shares (Diluted, Weighted) |
4.05 | 4.04 | 4.04 | 4.03 | |
Gross Margin |
6.28% | 40.72% | 91.37% | 167.09% | |
EBIT Margin |
(1,089.78%) | (602.14%) | (712.66%) | (476.17%) | |
EBT margin |
(669.57%) | (761.69%) | (905.19%) | (630.77%) | |
Net Profit Margin |
3,967.77% | 2,199.42% | 2,848.63% | 2,598.55% | |
Free Cash Flow Margin |
(824.19%) | (287.40%) | (74.72%) | (203.46%) | |
EBITDA |
(50.45) | (44.62) | (45.22) | (38.42) | |
EBIT |
(50.31) | (44.79) | (45.89) | (39.52) | |
EPS (Diluted, from Cont. Ops) |
(7.65) | (13.99) | (14.40) | (12.99) | |
EPS (Diluted, Consolidated) |
45.31 | 40.47 | 45.38 | 53.45 | |
EPS (Diluted, from Disc. Ops) |
— | 0.00 | 0.00 | 0.00 | |
EPS (Basic, Consolidated) |
45.31 | 40.47 | 45.38 | 53.45 | |
EPS (Basic, from Discontinued Ops) |
— | 54.45 | 59.77 | 66.37 | |
Shares (Diluted, Average) |
4.05 | 4.04 | 4.04 | 4.03 | |
EPS (Basic, from Continuous Ops) |
(7.65) | (13.99) | (14.40) | (12.99) | |
Income from Continuous Operations |
(30.91) | (56.57) | (58.20) | (52.26) | |
Income from Discontinued Operations |
— | 220.19 | 241.66 | 267.91 | |
Consolidated Net Income/Loss |
183.19 | 163.62 | 183.45 | 215.65 | |
EBITDA Margin |
(1,092.79%) | (599.80%) | (702.16%) | (463.00%) | |
Operating Cash Flow Margin |
(824.19%) | (287.40%) | (74.13%) | (203.78%) |
In millions of $ except per-share values · columns are period end dates · fundamentals updated 25 Oct 2026